FurrMoxi LP — Preservative-Free Post-Operative Ophthalmic Suspension
Advanced combination of moxifloxacin (4th-generation fluoroquinolone) and loteprednol etabonate (site-active ester corticosteroid) in a preservative-free format for reliable infection prophylaxis and controlled inflammation management.
Antibiotic + steroid in one formulation
Protects healing ocular surface
Potent steroid with safer profile
Ideal after cataract & cherry eye surgery
Clinical Overview & Rationale
FurrMoxi LP provides balanced dual therapy in a single, preservative-free suspension — addressing both infectious risk and inflammatory response in the delicate post-operative ocular environment.
🔬 How FurrMoxi LP Works
Moxifloxacin (4th-Generation Fluoroquinolone)
- Mechanism: Inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication
- Spectrum: Broad coverage — Gram-positive (Staphylococcus, Streptococcus), Gram-negative, and atypical pathogens
- Advantage: Superior ocular penetration compared to 2nd/3rd generation fluoroquinolones
- Clinical benefit: Effective prophylaxis against common post-surgical pathogens, including resistant strains
Loteprednol Etabonate (Site-Active Ester Steroid)
- Mechanism: Binds to glucocorticoid receptors, suppressing inflammatory mediators (prostaglandins, leukotrienes)
- Site-active design: Potent local anti-inflammatory action in ocular tissues
- Safety advantage: Rapid metabolism to inactive metabolites upon systemic absorption
- IOP benefit: Reduced risk of intraocular pressure elevation compared to prednisolone acetate or dexamethasone
- Clinical benefit: Ideal risk/benefit profile for post-operative inflammation control
Preservative-Free Formulation
- Avoids BAK toxicity: Benzalkonium chloride can cause epithelial cell damage, goblet cell loss, and corneal toxicity
- Critical in post-surgical eyes: Epithelium is already compromised and vulnerable
- Clinical benefit: Supports faster, healthier wound healing without additional chemical stress
👁️ Primary Indications
- Post-cataract surgery & phacoemulsification prophylaxis
- Third-eyelid (cherry eye) & adnexal procedures
- Entropion/ectropion correction & conjunctival surgeries
- Specialist-supervised short- to medium-term inflammatory management with infection risk
⚠️ CRITICAL CONTRAINDICATION
Do NOT use in active or suspected corneal ulceration. Topical corticosteroids may delay epithelial healing, promote collagenolysis, stromal thinning and increase perforation risk.
Always confirm corneal integrity (e.g., fluorescein staining, microbiology if indicated) before initiation.
💊 Dosing & Administration Protocols
Standard Post-Operative Protocol:
- Days 1-3: 1 drop per eye, 4 times daily (every 4-6 hours)
- Days 4-7: 1 drop per eye, 3 times daily
- Week 2: 1 drop per eye, 2 times daily (or as directed)
- Typical course duration: 7-14 days maximum
Post-Cataract Surgery:
- Initiate immediately post-procedure or Day 1
- Continue until inflammation controlled (typically 10-14 days)
- Monitor IOP if extended use required beyond 10 days
- Often combined with Vet Tears HA for surface protection
Cherry Eye / Third Eyelid Surgery:
- Begin day of surgery or Day 1 post-operatively
- Pair with Vet Tears HA for enhanced surface hydration
- Duration: 7-10 days typical, adjust based on healing
⚕️ Administration Guidelines
- Shake well before each use (suspension formulation)
- Wait 5-10 minutes between different ophthalmic medications
- Avoid touching dropper tip to eye or surrounding tissues
- Store at room temperature (15-25°C)
- Discard 4 weeks after opening to maintain sterility
⚕️ Safety, Monitoring & Precautions
🚫 Absolute Contraindications:
- Active corneal ulceration or epithelial defect (fluorescein-positive)
- Fungal or viral keratitis
- Mycobacterial ocular infections
- Known hypersensitivity to fluoroquinolones or corticosteroids
⚠️ Precautions & Monitoring:
- Monitor for secondary infections: Fungal or resistant bacterial infections can develop with prolonged steroid use
- Check IOP: If therapy extends beyond 10 days, monitor intraocular pressure
- Assess healing: Discontinue if no improvement after 48 hours or if condition worsens
- Corneal integrity: Recheck with fluorescein staining if any suspicion of ulceration develops
- Not for empiric use: Requires diagnosis-driven prescription under specialist supervision
📊 Monitoring Parameters:
- Corneal integrity (fluorescein staining at baseline and follow-up)
- Intraocular pressure (if extended use beyond 10 days)
- Signs of secondary infection (increased discharge, worsening inflammation)
- Resolution of inflammation (assess clinical improvement)
- Patient comfort (excessive tearing, squinting, or photophobia)
⚠️ Potential Adverse Effects
While generally well-tolerated, be aware of:
- Delayed wound healing (steroid component effect)
- Transient stinging or mild discomfort upon instillation
- Secondary fungal infections (rare, with prolonged use)
- Resistant bacterial infections (rare)
- IOP elevation (less common with loteprednol vs ketone steroids)
📋 Composition & Pack
- Moxifloxacin HCl equivalent to Moxifloxacin 0.5% w/v
- Loteprednol Etabonate 0.5% w/v
- Preservative-free suspension
Pack size: 5 mL multi-dose bottle
🔗 Clinical Integration & Combination Therapy
Often Used With:
Vet Tears HA — For enhanced ocular surface protection and comfort
FurrMoxi LP provides antimicrobial and anti-inflammatory cover, while Vet Tears HA supports tear film stability and epithelial healing. This combination is particularly valuable in cases where third-eyelid surgery may have reduced natural tear production.
Sample Combination Protocol:
Post-Cataract Surgery Protocol Example:
- Day 0 (Surgery): FurrMoxi LP 4x daily + Vet Tears HA 4x daily
- Days 1-7: Continue both medications 4x daily, monitor inflammation
- Days 8-14: Taper FurrMoxi LP to 2x daily, maintain Vet Tears HA 3-4x daily
- Week 3+: Discontinue FurrMoxi LP if inflammation resolved, continue Vet Tears HA as needed
Note: Wait 5-10 minutes between instilling different medications. Adjust protocol based on individual patient response and clinical assessment.
Expected Outcomes & Timeline:
- 24-48 hours: Initial reduction in inflammation and discomfort expected
- Days 3-5: Significant improvement in clinical signs (reduced hyperemia, discharge)
- Week 1-2: Continued resolution of inflammation, epithelial healing progressing
- If no improvement by 48-72 hours: Reassess diagnosis, consider culture/sensitivity, evaluate for complications
❓ Frequently Asked Questions
How long can FurrMoxi LP be used safely?
Typical post-operative courses are 7-14 days. Extended use beyond 14 days requires careful monitoring including IOP checks, as prolonged corticosteroid use can increase infection risk and IOP elevation risk (though loteprednol has a better safety profile than ketone steroids).
Can FurrMoxi LP be used in cats?
Yes, FurrMoxi LP is formulated for both dogs and cats. However, cats may be more sensitive to corticosteroid-induced IOP elevation, so careful monitoring is advised, especially with extended use.
What if the patient develops a corneal ulcer during treatment?
Discontinue FurrMoxi LP immediately. Topical corticosteroids are contraindicated in corneal ulceration. Switch to preservative-free antibiotic monotherapy and contact a veterinary ophthalmologist for guidance.
Why is preservative-free important for post-operative care?
Benzalkonium chloride (BAK), a common preservative in multi-dose eye drops, can damage corneal epithelium, delay wound healing, and cause additional inflammation. Post-surgical eyes are especially vulnerable, so preservative-free formulations support optimal healing.
How should FurrMoxi LP be stored after opening?
Store at room temperature (15-25°C). Keep bottle tightly closed when not in use. Discard 4 weeks after opening to ensure sterility and efficacy.
Can FurrMoxi LP be used for routine conjunctivitis?
No. FurrMoxi LP contains a corticosteroid and should only be used under specialist supervision for post-operative cases or specific inflammatory conditions where both antimicrobial and anti-inflammatory action is indicated. It is not for empiric use in routine conjunctivitis.
📚 References & Evidence Base
- Gelatt KN, Gilger BC. Veterinary Ophthalmology, 6th ed. Wiley-Blackwell; 2021. [Authoritative veterinary ophthalmology reference text]
- Comstock TL, Decory HH. Advances in corticosteroid therapy: loteprednol etabonate. Clin Ophthalmol. 2012;6:1113-1124. PMC3390479 → [Comprehensive review of loteprednol safety and efficacy profile]
- Moshirfar M, et al. Fourth-generation fluoroquinolones in ophthalmology. Expert Opin Pharmacother. 2007;8(11):1679-1689. PMID: 17685881 → [Review of moxifloxacin and 4th-gen fluoroquinolone advantages]
- Williams DL. Ocular preservative toxicity in veterinary practice. Vet Ophthalmol. 2008;11(Suppl 1):10-14. [Evidence for preservative-free formulation benefits in veterinary ophthalmology]
- Baudouin C, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease. The Ocular Surface. 2013;11(4):246-258. PMC4510730 → [Discussion of preservative-induced ocular surface disease and BAK toxicity]
- Kowalski RP, et al. The prevalence of bacteria, fungi, viruses, and acanthamoeba in 3,004 cases of keratitis. Eye Contact Lens. 2020;46(Suppl 1):S2-S7. PMID: 31498220 → [Epidemiology of ocular infections and antimicrobial resistance patterns]
- Rajpal RK, et al. Efficacy and safety of loteprednol etabonate 0.5% gel versus prednisolone acetate 1% in post-cataract surgery inflammation. J Ocul Pharmacol Ther. 2013;29(9):827-833. PMID: 23980546 → [Clinical trial demonstrating loteprednol efficacy with improved IOP safety profile]
- Hendrix DVH, et al. Diseases and surgery of the canine conjunctiva and nictitating membrane. Vet Clin North Am Small Anim Pract. 2015;45(4):797-813. PMID: 25956218 → [Veterinary guidance on third-eyelid surgery and post-operative management]
Need additional clinical evidence or full bibliography? Request our complete reference library →
For veterinary professional use only. Strictly under specialist supervision. Always follow current labelling and clinical judgement.
FurrMoxi LP – 5 mL Bottle
Explore Complementary Eye Care Solutions
Combine FurrMoxi LP with Vet Tears HA for comprehensive peri-operative protocols or integrate into your clinic's evidence-based ophthalmic pathways.
View Full Eye Care Portfolio